Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT06231368Phase 1Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2024
- Primary completion
- Nov 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inaticabtagene autoleucel in autoimmune hemolytic anemia (AIHA) and Evans syndrome, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence and severity of adverse events at 12 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
autoimmune hemolytic anemia (AIHA)Evans syndrome
Beyond the preview
Go deeper on NCT06231368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231368.